Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Daniel A. Laheru

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6646-0200; OpenAlex author ID A5033720986. Sources: ClinicalTrials.gov.

Their work

Papers
122 (first author 4, last author 13)
Trials
9 (principal investigator on 7)
Grants
0
Labs led
2
Collaborators
372
Papers, trials and grants by year

2002: 1 trial · 2003: none · 2004: none · 2005: 3 trials · 2006: 1 trial · 2007: none · 2008: 1 trial · 2009: none · 2010: 2 trials · 2011: 6 papers · 2012: 7 papers · 2013: 13 papers · 2014: 6 papers · 2015: 8 papers · 2016: 8 papers · 2017: 6 papers · 2018: 11 papers, 1 trial · 2019: 6 papers · 2020: 7 papers · 2021: 6 papers · 2022: 11 papers · 2023: 6 papers · 2024: 3 papers · 2025: 8 papers · 2026: 10 papers

Papers 50 of 122

  1. Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2026.102359↗
  2. Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. Co-author DOI 10.1038/s41467-026-68324-4↗
  3. The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II… Co-author DOI 10.1038/s41467-026-69294-3↗
  4. Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial Co-author DOI 10.1038/s41467-026-71968-x↗
  5. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Co-author DOI 10.1126/sciadv.aei1190↗
  6. First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts. Co-author DOI 10.1158/2159-8290.cd-25-2245↗
  7. Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma. Co-author DOI 10.3389/fimmu.2026.1715761↗
  8. Pain profiles in pancreatic cancer and chronic pancreatitis: a multicenter cross-sectional analysis. Co-author DOI 10.3389/fpain.2026.1903789↗
  9. Novel Genetic Risk Loci for Pancreatic Ductal Adenocarcinoma Identified in a Genome-wide Study of African Ancestry Individuals Co-author DOI 10.64898/2026.04.21.26351329↗
  10. Widespread Hyperalgesia Predicts Mortality in Pancreatic Adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353594↗
  11. Role of volumetric tumor enhancement on CT in predicting overall survival in patients with unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clinimag.2024.110365↗
  12. Value of radiomics features extracted from baseline computed tomography images in predicting overall survival in patients with nonsurgical pancreatic ductal ad… Co-author DOI 10.1016/j.gassur.2024.101882↗
  13. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  14. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Co-author DOI 10.1016/j.pan.2025.04.010↗
  15. A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcino… Co-author DOI 10.1158/1078-0432.ccr-24-3403↗
  16. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  17. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  18. Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic. Co-author DOI 10.1200/po-24-00494↗
  19. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-… Last author DOI 10.1002/cncr.35479↗
  20. Controversies in upper GI oncology: maintenance treatment in pancreatic cancer. First author DOI 10.1016/j.esmoop.2024.102244↗
  21. Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cells. Co-author DOI 10.1126/sciadv.adk1827↗
  22. Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of ab… Co-author DOI 10.1007/s00261-022-03693-0↗
  23. Tissue clearing and 3D reconstruction of digitized, serially sectioned slides provide novel insights into pancreatic cancer. Co-author DOI 10.1016/j.medj.2022.11.009↗
  24. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with r… Co-author DOI 10.1038/s41467-023-39196-9↗
  25. Association of Long-Term, New-Onset, and Postsurgical Diabetes With Survival in Patients With Resectable Pancreatic Cancer: A Retrospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000002257↗
  26. Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0230↗
  27. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a … Last author DOI 10.3389/fonc.2023.1250136↗
  28. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients trea… Co-author DOI 10.1002/cam4.4527↗
  29. Endoplasmic stress-inducing variants in CPB1 and CPA1 and risk of pancreatic cancer: A case-control study and meta-analysis. Co-author DOI 10.1002/ijc.33883↗
  30. Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy. Co-author DOI 10.1016/j.ccell.2022.10.001↗
  31. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  32. The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience. Co-author DOI 10.1067/j.cpradiol.2022.05.001↗
  33. Risk of Pancreatic Cancer in the Long-Term Prospective Follow-Up of Familial Pancreatic Cancer Kindreds. First author DOI 10.1093/jnci/djac167↗
  34. Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2767-9764.crc-22-0343↗
  35. RAD51B Harbors Germline Mutations Associated With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1200/po.21.00404↗
  36. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10663-1↗
  37. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderlin… Co-author DOI 10.1245/s10434-021-11202-8↗
  38. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and s… Co-author DOI 10.3857/roj.2021.01060↗
  39. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. Last author DOI 10.1016/j.canlet.2020.10.039↗
  40. Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.03.015↗
  41. Survival Outcomes of Adjuvant Chemotherapy Combined With Radiation Versus Chemotherapy Alone After Pancreatectomy for Distal Pancreatic Adenocarcinoma: A Singl… Co-author DOI 10.1097/mpa.0000000000001724↗
  42. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectabl… Last author DOI 10.1158/1078-0432.ccr-20-2974↗
  43. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  44. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Co-author DOI 10.20892/j.issn.2095-3941.2020.0273↗
  45. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2020.06.019↗
  46. Intraductal pancreatic cancer is less responsive than cancer in the stroma to neoadjuvant chemotherapy. Co-author DOI 10.1038/s41379-020-0572-6↗
  47. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Last author DOI 10.1038/s41416-019-0683-3↗
  48. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  49. A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-1025↗
  50. Metastatic Pancreatic Cancer: ASCO Guideline Update. Last author DOI 10.1200/jco.20.01364↗

Trials 9

  1. GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer Principal investigator NCT03161379↗
  2. Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer Principal investigator NCT01088789↗
  3. Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Principal investigator NCT01088815↗
  4. Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer T… Principal investigator NCT00727441↗
  5. Adjuvant GVAX Vaccine Therapy in Patients With Pancreatic Cancer Principal investigator NCT00389610↗
  6. Individualized Drug Treatment for Treating Patients With Pancreatic Cancer Study chair NCT00276744↗
  7. Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer Principal investigator NCT00305760↗
  8. Collecting and Storing Samples of Blood From Patients With Pancreatic Cancer and Healthy Participants Study chair NCT00898482↗
  9. Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas Principal investigator NCT00084383↗

Closest collaborators

The 25 strongest of 372 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lei Zheng · 49 shared papers, 2011–2026 · strength 4.60
  2. Dung Thi Le · 41 shared papers, 2011–2026 · strength 3.81
  3. Elizabeth M. Jaffee · 34 shared papers, 2011–2026 · strength 3.71
  4. Ana De Jesus‐Acosta · 33 shared papers, 1 shared trial, 2010–2026 · strength 3.15
  5. Amol Kumar Narang · 29 shared papers, 2012–2026 · strength 3.15
  6. Jin Peng He · 28 shared papers, 2015–2025 · strength 3.04
  7. Joseph M. Herman · 46 shared papers, 2011–2026 · strength 3.01
  8. Christopher Lee Wolfgang · 39 shared papers, 2011–2022 · strength 2.13
  9. Richard Andrew Burkhart · 17 shared papers, 2014–2026 · strength 2.05
  10. Ralph H. Hruban · 31 shared papers, 2011–2023 · strength 2.01
  11. Robert A. Anders · 17 shared papers, 2011–2026 · strength 1.85
  12. Michael Jon Pishvaian · 9 shared papers, 2017–2026 · strength 1.60
  13. Hao Wang · 9 shared papers, 2022–2026 · strength 1.51
  14. Amy Hacker‐Prietz · 21 shared papers, 2012–2025 · strength 1.48
  15. Katherine M. Bever · 10 shared papers, 2015–2026 · strength 1.45
  16. Nilofer Saba Azad · 11 shared papers, 2016–2026 · strength 1.38
  17. Matthew John Weiss · 18 shared papers, 2015–2022 · strength 1.36
  18. Timothy Michael Pawlik · 22 shared papers, 2011–2025 · strength 1.33
  19. Elliot K. Fishman · 18 shared papers, 2012–2023 · strength 1.31
  20. Michael Goggins · 11 shared papers, 2012–2026 · strength 1.18
  21. Neeha Zaidi · 6 shared papers, 2020–2026 · strength 1.12
  22. Arsen Osipov · 6 shared papers, 1 shared trial, 2018–2026 · strength 1.10
  23. Christopher L. Wolfgang · 12 shared papers, 2013–2025 · strength 1.07
  24. Eileen Mary O'Reilly · 9 shared papers, 2014–2025 · strength 1.01
  25. Mark M. Yarchoan · 7 shared papers, 2017–2026 · strength 0.99

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.